Transcode Therapeutics Ownership
| RNAZ Stock | USD 4.29 2.49 36.73% |
Transcode |
Transcode Stock Ownership Analysis
About 21.0% of the company shares are owned by institutional investors. The book value of Transcode Therapeutics was at this time reported as 3.16. The company recorded earning per share (EPS) of 5571.72. Transcode Therapeutics had not issued any dividends in recent years. The entity had 1:33 split on the 4th of December 2024. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Transcode Therapeutics contact Thomas MBA at 857 837 3099 or learn more at https://www.transcodetherapeutics.com.Transcode Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Transcode Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Transcode Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Transcode Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Transcode Therapeutics Outstanding Bonds
Transcode Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Transcode Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Transcode bonds can be classified according to their maturity, which is the date when Transcode Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TRANSCANADA PIPELINES LTD Corp BondUS893526DF78 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DJ90 | View | |
| TRANSATLANTIC HLDGS INC Corp BondUS893521AB05 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AB92 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AH62 | View | |
| US893574AF07 Corp BondUS893574AF07 | View | |
| TRPCN 55 15 SEP 79 Corp BondUS89356BAE83 | View | |
| TRPCN 5875 15 AUG 76 Corp BondUS89356BAB45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.